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Abstract  In  the  past,  needle  aspirations  or  injections  involving  the  motor  system  were  always
carried out  either  blind  or  guided  by  ﬂuoroscopy.  Over  the  last  few  years,  sonography  has
begun to  offer  an  interesting  alternative.  Its  advantages  are  that  it  is  a  relatively  inexpensive
technique,  while  not  emitting  ionising  radiation  and  being  easily  accessible.  There  has  been
a great  deal  of  technical  progress  including  high  frequency  transducers,  which  have  led  to
performance  improvements  in  terms  of  both  diagnosis  and  treatment  of  pathologies  of  the
motor system.  Due  to  these  technical  advances  and  to  sterile  covers  for  the  transducers,  it  is
now possible  to  visualise  and  to  aspirate  or  inject  into  a  peripheral  joint,  a  tendon  sheath  or
a bursa  with  or  without  effusion.  This  technique  does  not  require  a  contrast  medium  injection
because  the  needle  position  can  be  checked  directly.  Minimally  invasive,  it  allows  a  number  of
interventions  to  be  carried  out  with  a  very  low  complication  rate  since  the  entire  path  of  the
needle is  followed  using  sonography,  which  means  that  nerves,  vessels  and  other  structures  can
be avoided  because  they  are  visualised  directly  in  real  time.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
For  a  long  time,  ﬂuoroscopy-guided  injections  have  been  the  only  means  of  accurately
injecting  a  substance  into  a  joint  or  a  tendon  sheath.  While  joint  injections  are  often
carried  out  under  ﬂuoroscopy,  injections  to  the  soft  tissue  (bursa,  tendon  sheaths,  peri-
tendon)  are  for  the  main  part  carried  out  using  standard  injections.  It  is  difﬁcult  to  inject
with  certainty  into  a  structure  that  is  not  seen  directly  via  X-rays.  It  is  of  course  possible
to  use  an  iodine-based  contrast  medium  to  check  that  the  needle  is  in  the  right  position,
but  this  sometimes  involves  an  extensive  search  within  the  tissue  that  needs  to  be  crossed.
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TUltrasound-guided  injection  in  osteoarticular  pathologies  
When  we  speak  of  ultrasound-guided  techniques,  this
means  procedures  in  which  the  needle  is  followed  to  its  goal
in  real  time  and  this  does  not  include  injections  carried  out
by  marking  the  skin  of  the  area  to  be  injected  following  an
initial  ultrasound.  The  difference  is  clear  because  this  type
of  technique,  a  variation  of  a  standard  injection,  does  not
use  any  of  the  features  of  ultrasound-guiding.
The  advantages  of  ultrasound-guided  injection  are  clear,
given  that  it  contributes  to  reducing  risks  and  increases
patient  comfort:
• the  needle  reaches  its  goal  directly,  which  reduces  the
risk  of  vascular  or  nerve  puncture  and  the  possibility  of
potentially  harmful  inﬁltrations  directly  into  a  damaged
tendon  [1,2];
• the absence  of  radiation;
• a  reduced  risk  of  allergies  as  there  is  no  need  for  an  iodine-
based  contrast  medium.
If  the  necessity  for  routinely  using  image  guidance  for
these  injections  is  a  subject  for  debate,  then  good  sense  and
numerous  studies  should  prompt  us  to  do  so  [3—6]. Since  a
non-irradiating  technique  that  carries  minimal  risks  can  be
substituted  (ALARA  principle),  this  means  that  we  can  antic-
ipate  a  growing  role  for  ultrasonography  in  the  treatment  of
musculoskeletal  pathologies.
In  this  chapter,  we  discuss  the  basic  principles  of  these
injections,  in  the  knowledge  that  while  ultrasonography
seems  to  be  essential  for  injections  into  the  periarticular
soft  tissue,  it  is  also  ﬁnding  a  place  for  itself  in  some  joint
injections.
Precautions to take before the injection
As  with  all  injections,  the  patient  must  be  informed  about
the  procedure  and  their  informed  consent  must  be  col-
lected.  It  is  of  course  essential  to  check  that  the  patient
is  not  allergic  to  the  skin  disinfectants  or  any  of  the  prod-
ucts  to  be  injected,  in  view  of  the  fact  that  it  is  usually  easy
to  ﬁnd  a  substitute  or  to  perhaps  request  specialised  allergy
tests.  The  patient  must  also  be  asked  whether  he/she  is
taking  any  antiaggregant  or  anticoagulant  medication  [7]:
• if  the  patient  is  taking  vitamin  K  antagonists  (VKA)  [8]:
◦ for  intramuscular  or  deep  injections  (shoulder,  hip,
popliteal  fossa):  substitute  heparin,  which  should  itself
be  stopped  12  before  the  intervention  and  the  patient
should  have  an  INR  below  1.5  on  the  day  before  the
procedure,
◦ superﬁcial  ultrasound-guided  injections  can  be  carried
out  without  interrupting  VKA  as  long  as  the  patient  has
an  INR  of  between  2  and  3  on  the  day  before  the  pro-
cedure  (treatment  may  need  to  be  adjusted);
• if  the  patient  is  taking  platelet  antiaggregants:
◦ aspirin:  no  need  to  interrupt  treatment  at  doses  below
325  mg/day  [9],
◦ platelet  antiaggregants  such  as  clopidrogel  (Plavix®,
Clopilet®,  Ceruvin®),  ticlopidine  clorydrate  (Ticlid®):
the  clinician  responsible  for  this  treatment  should
preferably  be  asked  if  it  is  possible  to  interrupt  treat-
ment  at  least  ﬁve  days  before  the  intervention,  as
long  as  there  is  no  signiﬁcant  risk  that  outweighs  the
expected  beneﬁts  of  the  injection.  This  approach  is
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only  justiﬁed  when  the  patient  is  to  have  a  deep  injec-
tion  (shoulder,  hip,  popliteal  fossa);
heparin  (LMWH):  do  not  take  the  last  dose.
In  all  cases,  the  risks  and  beneﬁts  of  stopping  these  treat-
ents  must  be  considered.  The  clinician  should  also  ﬁnd  out
hether  the  patient  is  diabetic  or  immuno-suppressed,  and
hile  these  do  not  constitute  absolute  contraindications  to
he  intervention,  the  risks  and  beneﬁts  should  once  again  be
arefully  weighed  up  and  care  taken  with  aseptic  technique.
imilarly,  if  an  injection  is  to  take  place  close  to  a prosthesis
hen  prior  precautions  should  be  taken  in  terms  of  ensuring
hat  there  is  no  underlying  sepsis,  and  it  is  usual  to  con-
ult  the  surgeon  who  inserted  the  prosthesis  for  an  opinion.
t  the  slightest  suggestion  of  infection  on  the  day  of  the
njection,  the  intervention  will  need  to  be  postponed.  An
njection  of  cortisone  derivatives  into  a  joint  with  a  history
f  sepsis  is  contraindicated.  Pregnancy  is  not  a  contraindica-
ion  to  a  cortisone  derivative  injection.  The  best  course  of
ction  is  to  obtain  all  of  this  information  when  the  appoint-
ent  for  the  intervention  is  being  arranged,  and  a  patient
nformation  leaﬂet  and  informed  consent  form  need  to  be
iven  to  the  patient  at  the  same  time  for  them  to  bring  on
he  day  of  the  procedure,  completed  and  signed.  This  docu-
ent  will  explain  the  risks  that  are  common  to  all  injection
rocedures  and  these  will  not  be  detailed  in  this  article.
linicians  should  ensure  that  the  patient  has  understood  the
ocument  before  the  procedure  is  carried  out  and  provide
urther  explanation  if  necessary.  If  high-level  athletes  are
eceiving  a  glucocorticosteroid  injection,  they  have  to  make
 declaration  to  the  French  antidoping  agency  (document
vailable  on  the  agency’s  website).
iagnostic stage
ny  ultrasound-guided  injection  will  ﬁrst  include  a  diagnos-
ic  stage  in  order  to  conﬁrm  that  the  need  for  the  injection
s  well  founded  and  to  prepare  for  the  intervention.  These
ltrasound-guided  injections  do  therefore  require  perfect
astery  of  bone  and  joint  sonography.  This  diagnostic  stage
lso  allows  for  discussion  with  the  patient  and  for  questions
o  be  repeated  concerning  any  contraindications  that  the
atient  may  have  omitted  to  mention.  This  discussion  can
lso  be  the  time  to  provide  additional  information  on  how
he  intervention  will  proceed.  If,  after  the  diagnostic  stage,
he  intervention  seems  not  or  no  longer  to  be  indicated,  this
ust  be  explained  to  the  patient  and  the  clinician  informed.
ometimes  it  leads  to  a  slight  change  in  the  target  of  the
njection,  which  should  also  be  explained  to  the  patient  and
he  doctor  requesting  the  intervention  will  possibly  need  to
e  consulted  for  an  opinion.
hoice of transducer
he  choice  of  transducer  depends  on  the  site  to  be  injected.
he  transducer  chosen  for  the  injection  will  have  the  same
requency  as  that  used  for  the  diagnostic  stage.  In  general,
igher  frequency  transducers  are  used  for  the  extremities.
ome  small  joints  or  some  tendon  sheaths  are  easier  to
ccess  using  small  L-shaped  transducers  (Fig.  1).  Deeper
676  H.  Guerini  et  al.
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at  the  same  level  as  the  operator’s  arm  and  the  height  of  the
bed  may  need  to  be  adjusted  depending  on  the  injection.
We  use  a  system  that  enables  the  transducer  to  be  sus-
pended  above  the  site  for  injection  (by  means  of  a  telescopic
or  articulated  arm).  Use  of  an  articulated  arm  means  that
the  operator  can  work  with  their  hands  free,  by  releasing
the  transducer  which  remains  suspended  above  the  site  for
injection.  This  means  that  a  syringe  or  an  injection  prod-
uct  can  be  changed  with  no  difﬁculty  (Fig.  3).  A foot-switch
operated  image  capture  system  is  also  useful.
Aseptic technique
The  assistance  of  another  person  may  be  useful  in  carrying
out  this  intervention,  but  because  of  the  articulated  arm
system,  it  is  possible  to  carry  out  this  procedure  alone  with
a  little  training.
To  start  with,  the  transducer  previously  used  for  the  diag-
nostic  stage  should  be  cleaned  using  a  disinfectant  wipe.
Some  ultraviolet  disinfection  systems  can  be  used  [10]  but
they  complicate  the  intervention  and  do  not  guarantee  that
the  transducer  will  be  sterile,  in  which  case  a  physical
protective  barrier  consisting  of  an  airtight  sterile  sheath
is  always  required.  Next,  gel  is  applied  to  the  transducer,
which  is  still  suspended  from  the  articulated  arm.  It  is  impor-
tant  to  begin  by  cleaning  the  skin  following  the  technique
of  cleansing,  rinsing,  drying  and  using  an  antiseptic.  Once
the  patient’s  skin  is  disinfected,  the  operator  must  wash
their  hands  using  a gentle  soap  and  nail  brush  followed  by
disinfection  with  an  alcohol-based  hand  gel,  following  the
correct  procedure  for  each  product.  Sterile  gloves  must  also
be  used.  We  then  open  a  kit  containing  the  sterile  covering
for  the  transducer  that  includes  a  sterile  drape,  sterile  gel,igure 1. High frequency L-shaped transducer for injections in
ery peripheral sites.
njections  will  be  carried  out  using  a  lower  frequency  trans-
ucer  (Fig.  2).
ositioning the patient and preparing for
he  ultrasound
he  patient  must  always  be  lying  down  in  order  not  to  fall
f  he/she  begins  to  feel  unwell.  The  side  to  be  injected  is
ormally  next  to  the  ultrasound  system,  which  means  that
he  patient’s  position  may  need  to  be  adjusted  (head  at  the
op  or  bottom  of  the  bed).  The  area  to  be  injected  must  be
igure 2. Array transducer with broad bandwidth for deeper
njections.
a  sterile  polyurethane  sheath  and  elastic  bands  for  attach-
ing  the  transducer  (Fig.  4).  The  sterile  polyurethane  sheaths
are  the  same  type  as  those  used  for  covering  transduc-
ers  in  the  operating  theatre.  These  sheaths  have  generally
undergone  a  manufacturer’s  solidity  test  in  order  to  guaran-
tee  resistance.  The  possibility  of  tiny  perforations  cannot,
of  course,  be  avoided  entirely.  These  tiny  perforations
are  mainly  reported  with  latex  condoms  and  in  endorec-
tal  or  endovaginal  techniques  [10]. The  risk  remains  almost
Figure 3. Articulated arm allowing the transducer to remain cov-
ered and suspended above the patient.
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tFigure 4. Contents of a sterile kit (polyurethane sheath, sterile
gel, elastic band).
non-existent  for  polyurethane  sheaths  bearing  in  mind  that
the  literature  essentially  focuses  on  endoscopy  transducers
[11].  Once  the  sheath  is  placed  on  the  transducer,  the  sterile
gel  is  applied  ready  for  the  injection.
General rules
We  could  set  out  a  number  of  general  rules,  but  the  one
thing  to  remember  above  all  is  ‘‘use  the  conventional
approaches’’.  Because  of  the  freedom  that  ultrasonography
offers  in  terms  of  views  in  a  range  of  planes,  this  could  lead
operators  to  adjust  their  approach  to  each  different  situa-
tion.  However,  even  if  an  injection  can  be  adapted  to  suit  a
particular  case,  it  is  better  to  stick  to  approaches  that  are
proven  in  terms  of:
• an  absence  of  risks  to  nerves  and  vasculature;
• the  needle  being  clearly  visualised  in  relation  to  its  point
of  entry  to  the  skin  and  the  position  of  the  transducer.
Marking  the  skin  allows  the  landmarks  to  be  easily  located
again  after  disinfection  (Fig.  5).  This  is  done  while  avoid-
ing  making  a  mark  directly  at  the  injection  point.  A  point
of  entry  to  skin  must  be  made  that  is  away  from  the
Figure 5. Marking the skin with the transducer end allowing
the location and the direction to be reproduced after disinfection
(arrow). Second marking away from and above the puncture site.
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iigure 6. Simulation of a needle path parallel to the long axis of
he transducer allowing the needle to be perfectly visualised.
ltrasound  transducer  in  order  to  avoid  any  contact  between
he  transducer  and  the  needle.  It  is  not  always  easy  to  see
ow  this  can  be  done,  especially  for  small  joints  and  tendon
heaths,  in  view  of  the  prior  precautions  to  take  in  covering
he  transducer  with  a  sterile  sheath  and  using  sterile  gel.  In
hese  cases,  the  needle  should  be  introduced  under  the  skin
efore  the  transducer  is  positioned  nearby.
With  regard  to  needle  visibility,  it  is  important  to  work  out
hat  path  the  needle  will  follow  so  that  it  remains  as  parallel
s  possible  to  the  long  axis  of  the  transducer  (Fig.  6).  Indeed,
f  the  needle’s  angle  of  incline  increases  in  relation  to  the
urface  of  the  transducer  it  will  be  increasingly  difﬁcult  to
isualise.  It  is  also  advised  that  the  needle  should  not  be
nserted  with  the  transducer  perpendicular  to  the  long  axis
f  the  needle,  because  it  will  be  impossible  to  visualise  the
ntire  needle  in  a  single  view  during  the  procedure.  It  is  also
ossible  to  angle  the  needle  to  make  it  more  parallel  to  the
ransducer  leading  to  easier  insertion  into  tendon  sheaths.
It  is  easy  to  check  that  ﬂuid  is  diffusing  into  a  tendon
heath,  a  bursa  or  a  joint  by  observing  the  distribution  of
he  local  anaesthetic  or,  when  the  operator  is  certain  the
eedle  is  in  the  correct  position,  this  can  be  done  by  directly
y  observing  distribution  of  the  cortisone  derivative.  The
riteria  for  success  for  a  tendon  sheath,  bursa  or  joint  are
s  follows:
the ﬂuid  injected  conﬁrms  a  swelling  in  the  cavity  (Fig.  7);
the  product  injected  is  seen  to  diffuse  into  the  cavity,
being  visualised  in  Brownian  motion  (Fig.  8);
gas  bubbles  that  are  often  present  in  the  syringe  are  visu-
alised  diffusing  freely  within  the  cavity  or  the  tendon
sheath  injected  (Fig.  9).
njection of cortisone derivatives and
iscosupplementation
ortisone derivativesydrocortancyl® (Prednisolone  acetate),  with  its  weak  atro-
hying  action,  is  especially  indicated  for  peritendinous
njections.
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Figure 7. Distal longitudinal view of a ﬂexor tendon of the ﬁnger. The needle is positioned within the thickened tendon (a). Dilation of
the sheath after injection (b).
Figure 8. Axial view of the quadriceps tendon. Position of the transdu
Brownian motion (b, arrows).
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Digure 9. Coronal view of the supraspinatus tendon with a line of
as bubbles diffusing into the subacromial-deltoid bursa.
Altim® (cortivazol)  and  Diprostène® (Betamethasone
cetate  and  phosphate)  are  commonly  used  in  mechani-
al  or  inﬂammatory  joint  pathologies.  These  semi-delayed
roducts  have  a  relatively  long  action.
®Hexatrione (triamcinolone)  is  a  speciﬁc  type  of  delayed
orticosteroid;  it  has  a  prolonged  duration  of  action,  as  well
s  a  very  signiﬁcant  atrophying  effect  (achieved  by  destroy-
ng  synovial  tissue).  It  has  turned  out  to  perform  better
o
a
a
tcer within the effusion (a). Injection conﬁrmed to be successful by
han  other  corticosteroids,  especially  for  the  treatment  of
nﬂammatory  types  of  arthritis,  but  the  injection  must  be
ntra-articular,  without  raising  pressure,  given  that  extra-
rticular  injections  carry  the  risk  of  subcutaneous  atrophy
r  secondary  reﬂux.  It  is  therefore  formally  contraindicated
n  periarticular  pathologies.  It  is  especially  indicated  for
ocal  treatment  of  inﬂammatory  arthritis  or  crystal-induced
rthritis.  However,  whether  for  mechanical  or  inﬂammatory
athologies,  the  effects  of  a  corticosteroid  injection  are  usu-
lly  transient  and  require  alternation  with  overall  medical
nd/or  physical  management.
iscosupplementation
ntra-articular  injections  of  hyaluronic  acid  are  offered  as
 second  line  therapy,  after  other  medical  treatments  have
ailed,  in  painful  cases  of  osteoarthritis  with  little  or  no  effu-
ion,  that  are  moderate  on  radiology.  Hyaluronic  acid  is  an
lternative  to  non-steroidal  anti-inﬂammatory  drugs  when
hey  are  ineffective,  poorly  tolerated  or  contraindicated.
epending  on  the  product  and  the  joint  affected,  between
ne  and  three  injections  will  be  carried  out  at  a  rate  of  one
 week.  Hyaluronic  acid  is  a  local  treatment  with  delayed
nd  prolonged  action.  It  is  less  effective  than  a  corticos-
eroid  injection  for  the  ﬁrst  month  postinjection,  but  more
R[
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effective  after  one  month,  with  a  more  prolonged  effect
that  can  last  between  6  and  12  months  in  favourable  cases.
This  is  not  a  treatment  for  osteoarthritis  ﬂare-ups,  but  a
longer-term  maintenance  treatment.  Hyaluronic  acid  injec-
tions  can  be  preceded  by  a  corticosteroid  injection  if  there  is
joint  effusion.  These  injections  are  usually  carried  out  with-
out  support  for  the  knee  and  with  radiological  guidance  for
other  joints.  Nonetheless,  ultrasound-guiding  is  a  suitable
way  to  carry  out  a  hyaluronic  acid  injection  that  is  strictly
intra-articular.
After the intervention
After  all  injections,  the  joint  or  limb  concerned  must  be
rested  as  far  as  possible  for  48  hours.  For  some  people,
time  off  work  will  be  considered  and  it  is  best  prescribed
by  the  doctor  who  ordered  the  intervention.  Some  teams
recommend  immobilising  the  injected  site  for  48  hours  with
a  splint.  Naturally,  care  after  these  injections  must  include
the  usual  steps  for  the  treatment  of  rheumatic  or  mechanical
pathologies  (physiotherapy,  immobilisation,  systemic  treat-
ments).  In  principle,  the  patient  should  contact  a  doctor
(preferably  the  same  one  who  carried  out  the  procedure)
if  they  experience  any  complications  in  the  days  after  the
injection.  In  addition  to  the  risk  of  sepsis  (arthritis,  cel-
lulitis,  infectious  tenosynovitis),  aseptic  (chemical)  arthritis
that  resolves  spontaneously  and  certain  systemic  effects
linked  to  cortisone  derivatives  can  arise  in  the  days  following
these  injections  [12].
Conclusion
Ultrasound-guidance  of  injections  leads  to  almost  optimum
precision  and  safety  without  the  use  of  ionising  radiation  or
the  risk  of  allergy  to  iodine-based  contrast  media.  A  diag-
nostic  ultrasound  precedes  the  intervention  and  requires  the
operator  to  have  a  perfect  understanding  of  the  anatomy
and  the  disease.  If  aseptic  conditions  and  approaches  are
followed,  this  technique  will  hold  an  increasingly  important
role  in  the  arsenal  of  treatments  for  osteoarticular  disease
as  long  as  a  suitable  nomenclature  comes  to  light.Disclosure of interest
The  authors  declare  that  they  have  no  conﬂicts  of  interest
concerning  this  article.
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